DiscoverRARECastChanging a Treatment Landscape by De-Risking Drug Development
Changing a Treatment Landscape by De-Risking Drug Development

Changing a Treatment Landscape by De-Risking Drug Development

Update: 2025-11-13
Share

Description

Spinocerebellar ataxia is a group of inherited, heterogeneous neurodegenerative diseases affecting coordination, speech, and vision. There are currently no FDA approved therapies for the more than 50 known types of SCA​, but there is a growing pipeline of therapeutic candidates. We spoke to Andrew Rosen, CEO of the National Ataxia Foundation, about the challenges of developing therapies for spinocerebellar ataxia, the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Changing a Treatment Landscape by De-Risking Drug Development

Changing a Treatment Landscape by De-Risking Drug Development